Kyle Faget Interview Highlighted in Digital Health Regulations Year in Review
06 December 2022
Foley & Lardner LLP Partner Kyle Faget’s October interview with MedTech Insight is highlighted in their article, “Digital Health Regulations: A Year in Review,” which summarizes both the changes in digital health regulations in 2022 and what medical devices companies should look out for in the coming year.
Faget commented on the impact of the U.S. Food and Drug Administration’s (FDA) Clinical Decision Support Software (CDS) document, saying that some companies had to reevaluate whether their CDS products qualified as a device under the new guidance as the FDA took a broader approach to regulating that what was in its jurisdiction.
To read more about Faget’s earlier comments on this topic, click here.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”